Asimov Partners with Score Pharma to Develop Enhanced Anti-HER2 Antibody Therapeutics for Breast Cancer
核心洞察
Asimov (搜索) has announced a cell line development partnership with Score Pharma (搜索) to advance biosuperior antibody therapeutics, focusing initially on an enhanced anti-HER2 (搜索) trastuzumab for breast cancer (搜索) treatment.
Score Pharma (搜索)'s innovative technology reduces core fucosylation during antibody production to significantly increase Antibody-Dependent Cellular Cytotoxicity (ADCC (搜索)), potentially improving the efficacy of existing cancer (搜索) immunotherapies.
The collaboration will utilize Asimov (搜索)'s CHO Edge system, which includes a GS knock-out CHO host and computer-aided genetic design software, to enable Score Pharma (搜索)'s first clinical program.
Synthetic biology company Asimov (搜索) has entered into a cell line development partnership with Score Pharma (搜索), Inc., aimed at advancing biosuperior antibody therapeutics with enhanced anti-cancer (搜索) activity. The collaboration, announced on March 17, 2026, will initially focus on Score Pharma's lead program: a biosuperior anti-HER2 (搜索) trastuzumab for breast cancer (搜索) treatment.
Core Fucosylation Technology Enhances ADCC Activity
Score Pharma (搜索) has developed an innovative process technology that targets core fucosylation during antibody production. By reducing core fucose attached to therapeutic antibodies, the company aims to significantly increase Antibody-Dependent Cellular Cytotoxicity (ADCC (搜索)), a key immune mechanism by which therapeutic antibodies eliminate cancer (搜索) cells.
The technology works by enhancing the binding of natural killer cells to antibody-cancer (搜索) cell complexes, potentially improving the efficacy of existing antibody therapeutics. This approach represents a novel strategy for transforming existing, clinically proven antibody therapeutics to improve patient response.
CHO Edge Platform Enables Clinical Development
Through the partnership, Score Pharma (搜索) will leverage Asimov (搜索)'s CHO Edge system as the foundation for its proof-of-concept studies. The CHO Edge system incorporates several advanced components:
- A GS knock-out CHO host
- A hyperactive transposase
- A library of characterized genetic elements
- Kernel, Asimov's computer-aided genetic design software
"Biosuperior antibodies represent one of the most compelling opportunities in oncology today," said Alec Nielsen, co-founder and CEO at Asimov (搜索). "Approved antibodies can be modified to further enhance their therapeutic benefit, and Score Pharma (搜索)'s approach to modulating core fucosylation is a clever way to unlock that potential. We're proud that CHO Edge is the platform enabling their first clinical program."
Strategic Focus on Established Therapeutics
Score Pharma (搜索)'s approach centers on improving established antibody therapeutics rather than developing entirely new molecules. Bruce Edward Jones, Ph.D., Founder and CEO at Score Pharma, emphasized the company's mission: "Our potential to significantly improve established antibody therapeutics is second only to our passion for improving human health and is limited only by access to relevant cell lines. The Asimov (搜索) partnership makes our first clinically viable target possible."
The partnership represents a strategic alignment between Asimov (搜索)'s synthetic biology platform capabilities and Score Pharma (搜索)'s specialized antibody enhancement technology. Asimov, founded by bioengineers from MIT and Boston University and headquartered in Boston, has raised over $200 million from institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company.
Score Pharma (搜索)'s science-driven strategy focuses on disciplined execution to deliver transformative outcomes for patients while generating sustainable returns for shareholders. The company's dedication to developing more potent antibody therapeutics through transformation of existing, clinically proven molecules positions it uniquely in the competitive oncology landscape.